- Home
- HRMY vs RXRX Comparison
HRMY vs RXRX Comparison
Compare HRMY & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- RXRX
- Stock Information
- Founded
- HRMY 2017
- RXRX 2013
- Country
- HRMY United States
- RXRX United States
- Employees
- HRMY N/A
- RXRX N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- RXRX Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- RXRX Health Care
- Exchange
- HRMY Nasdaq
- RXRX Nasdaq
- Market Cap
- HRMY 1.8B
- RXRX 2.0B
- IPO Year
- HRMY 2020
- RXRX 2021
- Fundamental
- Price
- HRMY $34.43
- RXRX $5.46
- Analyst Decision
- HRMY Strong Buy
- RXRX Buy
- Analyst Count
- HRMY 9
- RXRX 5
- Target Price
- HRMY $54.44
- RXRX $7.00
- AVG Volume (30 Days)
- HRMY 594.8K
- RXRX 29.1M
- Earning Date
- HRMY 08-05-2025
- RXRX 08-07-2025
- Dividend Yield
- HRMY N/A
- RXRX N/A
- EPS Growth
- HRMY 13.13
- RXRX N/A
- EPS
- HRMY 2.62
- RXRX N/A
- Revenue
- HRMY $744,852,000.00
- RXRX $59,790,000.00
- Revenue This Year
- HRMY $20.33
- RXRX $23.85
- Revenue Next Year
- HRMY $17.67
- RXRX $43.06
- P/E Ratio
- HRMY $13.30
- RXRX N/A
- Revenue Growth
- HRMY 20.62
- RXRX 29.32
- 52 Week Low
- HRMY $26.47
- RXRX $3.79
- 52 Week High
- HRMY $41.61
- RXRX $12.36
- Technical
- Relative Strength Index (RSI)
- HRMY 64.26
- RXRX 52.97
- Support Level
- HRMY $33.76
- RXRX $5.19
- Resistance Level
- HRMY $35.08
- RXRX $5.88
- Average True Range (ATR)
- HRMY 0.87
- RXRX 0.36
- MACD
- HRMY 0.34
- RXRX 0.01
- Stochastic Oscillator
- HRMY 92.43
- RXRX 47.18
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.